Retacrit Injection, Solution
Product Images NDC 59353-004

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Retacrit (NDC 59353-004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vifor (international) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Retacrit 01)

An instructional diagram illustrating components used for injection including a vial, a disposable syringe labeled with needle cover, plunger rod, and syringe barrel with markings; alcohol wipes; a cotton ball; and a puncture-proof container marked with a biohazard symbol for safe disposal.*

FDA Label Image

Logo (Retacrit 01a)

FDA Label Image

Logo (Retacrit 01b)

FDA Label Image

Figure 2 (Retacrit 02)

An instructional illustration showing hands being washed under running water from a faucet, depicting the process of hand hygiene.*

FDA Label Image

Figure 3 (Retacrit 03)

An illustration showing a hand holding a vial or small bottle, depicted in a simple line drawing style. The image appears instructional, possibly indicating how to hold an injection vial for use.*

FDA Label Image

Figure 4 (Retacrit 04)

An instructional illustration showing a person opening a vial by removing the top cap with one hand while holding the vial with the other hand. This image is typically used in medication preparation guidance for injection solutions.*

FDA Label Image

Figure 5 (Retacrit 05)

Instructional illustration showing a hand holding a syringe and vial, demonstrating to "Pull Straight Off" the vial cap as indicated by a leftward arrow. This image depicts a step for preparing an injection solution.*

FDA Label Image

Figure 6 (Retacrit 06)

Illustration showing a pair of hands holding a syringe and vial, demonstrating proper technique for drawing medication from the vial into the syringe. This instructional image depicts the preparation step for an injection.*

FDA Label Image

Figure 7 (Retacrit 07)

An instructional illustration showing a hand withdrawing fluid with a syringe from a vial, demonstrating proper technique for preparing an injection solution. The image is simple and focused on the manipulation of the vial and syringe.*

FDA Label Image

Figure 8 (Retacrit 08)

An instructional black-and-white line drawing illustrating hands preparing an injection. One hand holds a vial, and the other hand uses a syringe to withdraw liquid from the vial, demonstrating proper technique for drawing medication into the syringe.*

FDA Label Image

Figure 9 (Retacrit 09)

An instructional illustration showing a hand holding a syringe with labeled parts: needle and plunger. The image demonstrates handling or preparing the injection device, likely related to subcutaneous or intravenous administration of the drug.*

FDA Label Image

Figure 10 (Retacrit 10)

An instructional line drawing showing a hand holding a syringe with the needle labeled, and the other hand holding the syringe's plunger, demonstrating the preparation or use of an injection device.*

FDA Label Image

Figure 11 (Retacrit 11)

An anatomical diagram illustrating recommended injection sites for RETACRIT (epoetin alfa-epbx) solution. Shaded areas show preferred injection locations on the front and back of the body, including the abdomen, upper arms, thighs, and buttocks.*

FDA Label Image

Figure 12 (Retacrit 12)

An instructional line drawing illustrating the administration of an injection into the upper thigh, showing a hand holding a syringe positioned above the skin target area.*

FDA Label Image

Figure 13 (Retacrit 13)

An instructional line drawing showing a hand holding a syringe poised to inject into the upper thigh, illustrating a subcutaneous injection site on the thigh area.*

FDA Label Image

Figure 14 (Retacrit 14)

An instructional diagram showing a hand holding a syringe at an angle above a bent knee, illustrating the subcutaneous injection technique. The angles depicted include 45 degrees and 90 degrees relative to the skin surface.*

FDA Label Image

Figure 15 (Retacrit 15)

An instructional illustration showing a hand pressing a small rectangular object against an injection device or tubing, likely demonstrating a step in device operation or preparation related to injection administration.*

FDA Label Image

Figure 16 (Retacrit 16)

An instructional diagram showing a syringe needle poised above a vial or injection device. Two tubing lines are connected to the injection device, illustrating preparation or administration of an injection solution, consistent with an intravenous or subcutaneous route.*

FDA Label Image

Logo (Retacrit 16a)

FDA Label Image

Principal Display Panel (2,000 Units/mL Vial Label)

Label for Retacrit epoetin alfa-epbx injection, solution 2,000 Units/mL in a 1 mL single-dose vial. The label includes storage instructions (2°C to 8°C), manufacturer information (Hospira, Inc., a Pfizer Company), distributor information (Vifor International Inc., Switzerland), and a barcode area with placeholders for lot and expiration dates.*

FDA Label Image

Principal Display Panel (2,000 Units/mL Vial Carton)

Retacrit 2,000 Units/mL injection, solution label for epoetin alfa-epbx recombinant, intended for intravenous or subcutaneous use. The label includes dosage strength, manufacturer Vifor Pharma, and storage instructions. Packaging indicates single-dose vials of 1 mL containing 2,000 Units of epoetin alfa-epbx each, sterile solution with no preservative, distributed by Vifor (International) Inc.*

FDA Label Image

Principal Display Panel (3,000 Units/mL Vial Label)

Label for Retacrit (epoetin alfa-epbx) injection, 3,000 Units/mL, in a 1 mL single-dose vial. The label includes storage instructions, dosage information to refer to prescribing info, manufacturer Hospira, Inc. (Pfizer) in Lake Forest, IL, and distributor Vifor (International) Inc. in Switzerland. It also features a barcode, lot number, and expiration date fields.*

FDA Label Image

Principal Display Panel (3,000 Units/mL Vial Carton)

Packaging label for Retacrit 3,000 Units/mL injection solution, containing epoetin alfa-epbx recombinant. The label indicates single-dose vials for intravenous or subcutaneous use. Distributed by Vifor (International) Inc, the label includes storage instructions, ingredient details, and manufacturer info for Hospira, Inc. The label highlights the absence of preservatives in the sterile solution.*

FDA Label Image

Principal Display Panel (4,000 Units/mL Vial Label)

Label for Retacrit 4000 Units/mL injection solution, containing epoetin alfa-epbx recombinant. It is a 1 mL single-dose vial produced by Hospira, Inc. (a Pfizer company) in the USA, and distributed by Vifor (International) Inc. The label includes storage instructions at 2° to 8°C, dosage referencing prescribing information, and space for lot number and expiration date.*

FDA Label Image

Principal Display Panel (4,000 Units/mL Vial Carton)

Packaging label for Retacrit 4,000 Units/mL Injection, Solution, containing epoetin alfa-epbx recombinant. The label indicates it is for intravenous or subcutaneous use only, single-dose vial. It is manufactured by Hospira, Inc., a Pfizer Company, and distributed by Vifor (International) Inc. The label includes dosing, storage instructions, ingredient listing, and warnings about phenylalanine content.*

FDA Label Image

Principal Display Panel (10,000 Units/mL Vial Label)

Label for Retacrit (epoetin alfa-epbx) injection solution, 10,000 Units/mL strength, presented in a 1 mL single-dose vial. The label includes storage instructions at 2°C to 8°C, manufacturing information by Hospira, Inc. (a Pfizer Company, Lake Forest, IL), and distribution by Vifor (International) Inc., Switzerland. It also shows a GS1 DataBar and placeholders for lot and expiration date.*

FDA Label Image

Principal Display Panel (10,000 Units/mL Vial Carton)

Packaging label for Retacrit 10,000 Units/mL injection solution, containing epoetin alfa-epbx recombinant. The label indicates the product is a single-dose vial solution for intravenous or subcutaneous use, sterile with no preservative. The labeler is Vifor Pharma. The package contains 10 single-dose vials, each 1 mL with 10,000 units of epoetin alfa-epbx.*

FDA Label Image

Retacrit 25

Retacrit 20,000 Units/mL injection, solution label on a 1 mL multiple-dose vial. Contains epoetin alfa-epbx recombinant. Labeled for prescription use, storing at 2°C to 8°C, with manufacturing by Hospira, Inc., a Pfizer Company, and distribution by Vifor (International) Inc., Switzerland.*

FDA Label Image

Retacrit 26

Retacrit 20,000 Units/mL injection solution carton label for epoetin alfa-epbx recombinant. The label shows this is a sterile, multiple-dose vial for intravenous or subcutaneous use. It includes the drug name, strength, dosage form, dosing instructions, and the Vifor Pharma logo with NDC 59353-120-10. The product is labeled Rx only.*

FDA Label Image

Retacrit 27

Label for Retacrit (epoetin alfa-epbx) injection, solution, 20,000 Units/2 mL (10,000 Units/mL) in a 2 mL multiple-dose vial. The label includes storage instructions at 2°C to 8°C, manufacturer Hospira Inc., a Pfizer Company, and distributor Vifor (International) Inc., Switzerland. Barcode and lot/expiration date placeholders are visible.*

FDA Label Image

Retacrit 28

Packaging label for Retacrit injection solution containing epoetin alfa-epbx recombinant. The label indicates a strength of 20,000 Units per 2 mL (10,000 Units/mL) and specifies use for intravenous or subcutaneous administration. It is a sterile, preserved multiple-dose vial product distributed by Vifor Pharma.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.